The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans
Abstract
The vanilloid receptor TRPV1 has been identified as a molecular target for the treatment of pain associated with inflammatory diseases and cancer. Hence, TRPV1 antagonists have been considered for therapeutic evaluation in such diseases. During Phase I clinical trials with AMG 517, a highly selective TRPV1 antagonist, we found that TRPV1 blockade elicited marked, but reversible, and generally plasma concentration-dependent hyperthermia. Similar to what was observed in rats, dogs, and monkeys, hyperthermia was attenuated after repeated dosing of AMG 517 (at the highest dose tested) in humans during a second Phase I trial. However, AMG 517 administered after molar extraction (a surgical cause of acute pain) elicited long-lasting hyperthermia with maximal body temperature surpassing 40 degrees C, suggesting that TRPV1 blockade elicits undesirable hyperthermia in susceptible individuals. Mechanisms of AMG 517-induced hyperthermia were then studied in rats. AMG 517 caused hyperthermia by inducing tail skin vasoconstriction and increasing thermogenesis, which suggests that TRPV1 regulates vasomotor tone and metabolic heat production. In conclusion, these results demonstrate that: (a) TRPV1-selective antagonists like AMG 517 cannot be developed for systemic use as stand alone agents for treatment of pain and other diseases, (b) individual susceptibility influences magnitude of hyperthermia observed after TRPV1 blockade, and (c) TRPV1 plays a pivotal role as a molecular regulator for body temperature in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impaired nociception and pain sensation in mice lacking the capsaicin receptor
Caterina, M. J., Leffler, A., Malmberg, A. B., Martin, W. J., Trafton, J., Petersen-Zeitz, K. R., Koltzenburg, M., Basbaum, A. I., & Julius, D. (2000) · Science · doi:10.1126/science.288.5464.306 · Cited by 3,544
Molecular mechanisms of nociception
Julius, D., & Basbaum, A. I. (2001) · Nature · doi:10.1038/35093019 · Cited by 2,685 · cited 1×
“7), capsaicin, resiniferatoxin, components of the ‘‘inflammatory soup,” products of lipoxygenase, and G-protein coupled receptor signaling, making it a molecular integrator of pain transduction [1,14,17,29].”
BackgroundVanilloid (Capsaicin) Receptors and Mechanisms
Szallasi, A., & Blumberg, P. M. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01403-0 · Cited by 1,903
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
Davis, J. B., Gray, J., Gunthorpe, M. J., Hatcher, J. P., Davey, P. T., Overend, P., Harries, M. H., Latcham, J., Clapham, C., Atkinson, K., et al. (2000) · Nature · doi:10.1038/35012076 · Cited by 1,760
The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway
Caterina, M. J., & Julius, D. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.487 · Cited by 1,575
Ji, R.-R., Samad, T. A., Jin, S.-X., Schmoll, R., & Woolf, C. J. (2002) · Neuron · doi:10.1016/s0896-6273(02)00908-x · Cited by 1,238
The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept
Szallasi, A., Cortright, D. N., Blum, C. A., & Eid, S. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2280 · Cited by 879
Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system
Romanovsky, A. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00668.2006 · Cited by 786
Self-citationGavva, N. R., Tamir, R., Qu, Y., Klionsky, L., Zhang, T. J., Immke, D., Wang, J., Zhu, D., Vanderah, T. W., Porreca, F., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079855 · Cited by 390
Self-citationSelective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
Ghilardi, J. R., Röhrich, H., Lindsay, T. H., Sevcik, M. A., Schwei, M. J., Kubota, K., Halvorson, K. G., Poblete, J., Chaplan, S. R., Dubin, A. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3815-04.2005 · Cited by 384
Cited by
Julius, D. (2013) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101011-155833 · Cited by 1,140
Transient receptor potential channels: targeting pain at the source
Patapoutian, A., Tate, S., & Woolf, C. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2757 · Cited by 646
Wu, L.-J., Sweet, T.-B., & Clapham, D. E. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002725 · Cited by 602
Transient receptor potential channels as therapeutic targets
Moran, M. M., McAlexander, M. A., Bíró, T., & Szallasi, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3456 · Cited by 550
Advances in TRP channel drug discovery: from target validation to clinical studies
Koivisto, A.-P., Belvisi, M. G., Gaudet, R., & Szallasi, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00268-4 · Cited by 537
Skin temperature: its role in thermoregulation
Romanovsky, A. A. (2014) · Acta Physiologica · doi:10.1111/apha.12231 · Cited by 518
Self-citationZhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Nilius, B., & Szallasi, A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008268 · Cited by 506
Fattori, V., Hohmann, M., Rossaneis, A., Pinho-Ribeiro, F., & Verri, W. (2016) · Molecules · doi:10.3390/molecules21070844 · Cited by 479
Peripheral thermosensation in mammals
Vriens, J., Nilius, B., & Voets, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3784 · Cited by 446
Transient receptor potential (TRP) channels: a clinical perspective
Kaneko, Y., & Szallasi, A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12414 · Cited by 370
Wong, G. Y., & Gavva, N. R. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.006 · Cited by 351
Self-citationUnravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain
O'Neill, J., Brock, C., Olesen, A. E., Andresen, T., Nilsson, M., & Dickenson, A. H. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.006163 · Cited by 348
Molecular Mechanism of TRP Channels
Zheng, J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120001 · Cited by 335
TRPV1‐lineage neurons are required for thermal sensation
Mishra, S. K., Tisel, S. M., Orestes, P., Bhangoo, S. K., & Hoon, M. A. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.325 · Cited by 307
The thermo‐TRP ion channel family: properties and therapeutic implications
Vay, L., Gu, C., & McNaughton, P. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01601.x · Cited by 296
Targeting TRP channels for pain relief
Brederson, J.-D., Kym, P. R., & Szallasi, A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.003 · Cited by 293
North, R. Y., Li, Y., Ray, P., Rhines, L. D., Tatsui, C. E., Rao, G., Johansson, C. A., Zhang, H., Kim, Y. H., Zhang, B., et al. (2019) · Brain · doi:10.1093/brain/awz063 · Cited by 282
Acid-Sensitive Ion Channels and Receptors
Holzer, P. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-79090-7_9 · Cited by 282
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
Clapham, D. E., & Miller, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117485108 · Cited by 264
McCoy, E. S., Taylor-Blake, B., Street, S. E., Pribisko, A. L., Zheng, J., & Zylka, M. J. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.030 · Cited by 263
The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not
Romanovsky, A. A., Almeida, M. C., Garami, A., Steiner, A. A., Norman, M. H., Morrison, S. F., Nakamura, K., Burmeister, J. J., & Nucci, T. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001263 · Cited by 253
Self-citationThe thermoregulation system and how it works
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63912-7.00001-1 · Cited by 186
Self-citationGarami, A., Shimansky, Y. P., Rumbus, Z., Vizin, R. C. L., Farkas, N., Hegyi, J., Szakacs, Z., Solymar, M., Csenkey, A., Chiche, D. A., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107474 · Cited by 159
“RK and DJK are employed by Purdue Pharma LP. AAR is an officer and director of Catalina Pharma Inc. and Zharko Pharma Inc.; hehas consulted for TRPV1programs at several pharmaceutical companies, and his laboratory conducted paid research on TRPV1 for Amgen Inc., Abbott Laboratories, and AbbVie Inc.”
BackgroundSelf-citationCosta, B., Bettoni, I., Petrosino, S., Comelli, F., Giagnoni, G., & Di Marzo, V. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.02.001 · Cited by 64
Modulation of defensive behavior by transient receptor potential vanilloid type-1 (TRPV1) channels
Aguiar, D. C., Moreira, F. A., Terzian, A. L., Fogaça, M. V., Lisboa, S. F., Wotjak, C. T., & Guimaraes, F. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.026 · Cited by 57
TRPA1 mediates the hypothermic action of acetaminophen
Gentry, C., Andersson, D. A., & Bevan, S. (2015) · Scientific Reports · doi:10.1038/srep12771 · Cited by 50
Go, E. J., Hwang, S.-M., Jo, H., Rahman, M. M., Park, J., Lee, J. Y., Jo, Y. Y., Lee, B.-G., Jung, Y., Berta, T., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01342-8 · Cited by 28
Metadata
- Authors
- Gavva, N. R., Treanor, J. J. S., Garami, A., Fang, L., Surapaneni, S., Akrami, A., Alvarez, F., Bak, A., Darling, M., Gore, A., Jang, G. R., Kesslak, J. P., Ni, L., Norman, M. H., Palluconi, G., Rose, M. J., Salfi, M., Tan, E., Romanovsky, A. A., Banfield, C., & Davar, G.
- Venue
- Pain
- Published
- 2008-05
- Volume
- 136
- Issue
- 1
- Pages
- 202-210
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2007034094
- Cited by
- 525
- References
- 31
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.